PROFIT SLUMP: Biotech giant Amgen Inc.’s fourth-quarter net income dropped 16 percent to $788 million, or $1.01 per share, due to higher spending on production, marketing, research and other items.
SALES SURGE: Revenue rose 11 percent to $4.42 billion, as sales of immune disorder treatment Enbrel and four other drugs climbed by double digits. But part of the revenue jump was due to price increases.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.